Total wrist arthroplasty with the Freedom® prosthesis: a short-term follow-up.

Autor:	Brown M; Wrightington Hospital, Appley Bridge, Wigan, Lancashire, UK., Wharton R; Wrightington Hospital, Appley Bridge, Wigan, Lancashire, UK., Begum R; Wrightington Hospital, Appley Bridge, Wigan, Lancashire, UK., Trail I; Wrightington Hospital, Appley Bridge, Wigan, Lancashire, UK., Hayton M; Wrightington Hospital, Appley Bridge, Wigan, Lancashire, UK., Talwalkar S; Wrightington Hospital, Appley Bridge, Wigan, Lancashire, UK.
Jazyk:	angličtina
Zdroj:	The Journal of hand surgery, European volume [J Hand Surg Eur Vol] 2024 Jan; Vol. 49 (1), pp. 40-47. Date of Electronic Publication: 2023 Sep 11.
DOI:	10.1177/17531934231193119
Abstrakt:	We retrospectively reviewed our series of primary total wrist arthroplasty with the Freedom® prosthesis. The primary outcome measure was revision, and secondary measures included radiographic loosening, pain, complications, movement range, grip strength and patient-reported measures. We reviewed 12 implants in 11 patients (mean age 59 years, range 45-80) with a mean radiological and clinical follow-up of 2.7 and 3 years, respectively. One radial component failed to integrate and was revised at Day 84. Four carpal components demonstrated areas of lucency. There was a statistically significant reduction in pain, and total flexion-extension increased. Despite high patient satisfaction on a ten-point visual analogue scale score (mean 8.7 out of 10), the mean patient-rated wrist evaluation, Quick Disabilities of the Arm, Shoulder and Hand and Patient Evaluation Measure scores were 52, 55 and 53, respectively. The Freedom® implant reduced pain and preserved wrist movement in our patients; however, annual surveillance is recommended due to the high incidence of early carpal component lucency. Level of evidence: IV. Competing Interests: Declaration of conflicting interestsThe authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Sumedh Talwalkar was a consultant for Integra LifeSciences and is now a consultant for Smith & Nephew. The other authors declare no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu